Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons

A. Mocroft, JD. Lundgren, JK. Rockstroh, I. Aho, G. Wandeler, L. Nielsen, S. Edwards, JP. Viard, K. Lacombe, G. Fätkenheuer, G. Guaraldi, M. Laguno, J. Llibre, H. Elinav, L. Flamholc, M. Gisinger, D. Paduta, I. Khromova, D. Jilich, B....

. 2020 ; 7 (12) : ofaa470. [pub] 20201007

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc21010240

Background: The role of hepatitis C virus (HCV) coinfection and HCV-RNA in the development of diabetes mellitus (DM) in HIV-positive persons remains unclear. Methods: Poisson regression was used to compare incidence rates of DM (blood glucose >11.1 mmol/L, HbA1C >6.5% or >48 mmol/mol, starting antidiabetic medicine or physician reported date of DM onset) between current HIV/HCV groups (anti-HCV-negative, spontaneously cleared HCV, chronic untreated HCV, successfully treated HCV, HCV-RNA-positive after HCV treatment). Results: A total of 16 099 persons were included; at baseline 10 091 (62.7%) were HCV-Ab-negative, 722 (4.5%) were spontaneous clearers, 3614 (22.4%) were chronically infected, 912 (5.7%) had been successfully treated, and 760 (4.7%) were HCV-RNA-positive after treatment. During 136 084 person-years of follow-up (PYFU; median [interquartile range], 6.9 [3.6-13.2]), 1108 (6.9%) developed DM (crude incidence rate, 8.1/1000 PYFU; 95% CI, 7.7-8.6). After adjustment, there was no difference between the 5 HCV strata in incidence of DM (global P = .33). Hypertension (22.2%; 95% CI, 17.5%-26.2%) and body mass index >25 (22.0%; 95% CI, 10.4%-29.7%) had the largest population-attributable fractions for DM. Conclusions: HCV coinfection and HCV cure were not associated with DM in this large study. The biggest modifiable risk factors were hypertension and obesity, and continued efforts to manage such comorbidities should be prioritized.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21010240
003      
CZ-PrNML
005      
20210610101353.0
007      
ta
008      
210413s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ofid/ofaa470 $2 doi
035    __
$a (PubMed)33409325
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Mocroft, Amanda $u Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK
245    10
$a Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons / $c A. Mocroft, JD. Lundgren, JK. Rockstroh, I. Aho, G. Wandeler, L. Nielsen, S. Edwards, JP. Viard, K. Lacombe, G. Fätkenheuer, G. Guaraldi, M. Laguno, J. Llibre, H. Elinav, L. Flamholc, M. Gisinger, D. Paduta, I. Khromova, D. Jilich, B. Rozplochowski, C. Oprea, L. Peters, EuroSIDA study
520    9_
$a Background: The role of hepatitis C virus (HCV) coinfection and HCV-RNA in the development of diabetes mellitus (DM) in HIV-positive persons remains unclear. Methods: Poisson regression was used to compare incidence rates of DM (blood glucose >11.1 mmol/L, HbA1C >6.5% or >48 mmol/mol, starting antidiabetic medicine or physician reported date of DM onset) between current HIV/HCV groups (anti-HCV-negative, spontaneously cleared HCV, chronic untreated HCV, successfully treated HCV, HCV-RNA-positive after HCV treatment). Results: A total of 16 099 persons were included; at baseline 10 091 (62.7%) were HCV-Ab-negative, 722 (4.5%) were spontaneous clearers, 3614 (22.4%) were chronically infected, 912 (5.7%) had been successfully treated, and 760 (4.7%) were HCV-RNA-positive after treatment. During 136 084 person-years of follow-up (PYFU; median [interquartile range], 6.9 [3.6-13.2]), 1108 (6.9%) developed DM (crude incidence rate, 8.1/1000 PYFU; 95% CI, 7.7-8.6). After adjustment, there was no difference between the 5 HCV strata in incidence of DM (global P = .33). Hypertension (22.2%; 95% CI, 17.5%-26.2%) and body mass index >25 (22.0%; 95% CI, 10.4%-29.7%) had the largest population-attributable fractions for DM. Conclusions: HCV coinfection and HCV cure were not associated with DM in this large study. The biggest modifiable risk factors were hypertension and obesity, and continued efforts to manage such comorbidities should be prioritized.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lundgren, Jens D $u CHIP, Rigshospitalet, Copenhagen, Denmark
700    1_
$a Rockstroh, Juergen K $u University Hospital Bonn, Bonn, Germany
700    1_
$a Aho, Inka $u Helsinki University Hospital, Helsinki, Finland
700    1_
$a Wandeler, Gilles $u Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland
700    1_
$a Nielsen, Lars $u Nordsjællands Hospital, Hillerød, Denmark
700    1_
$a Edwards, Simon $u Mortimer Market Centre, London, UK
700    1_
$a Viard, Jean-Paul $u Hôtel-Dieu, AP-HP, Paris, France
700    1_
$a Lacombe, Karine $u Sorbonne Université, IPLESP Inserm UMR-S1136, AP-HP, Paris, France
700    1_
$a Fätkenheuer, Gerd $u University Hospital of Cologne, Cologne, Germany
700    1_
$a Guaraldi, Giovanni $u University of Modena and Reggio Emilia, Modena, Italy
700    1_
$a Laguno, Montserrat $u Hospital Clinic, Barcelona, Spain
700    1_
$a Llibre, Josep $u University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
700    1_
$a Elinav, Hila $u Hadassah Hospital, Jerusalem, Israel
700    1_
$a Flamholc, Leo $u Skane University Hospital, Malmö, Sweden
700    1_
$a Gisinger, Martin $u Medical University of Innsbruck, Innsbruck, Austria
700    1_
$a Paduta, Dzmitry $u Gomel Regional Centre for Hygiene, Gomel, Belarus
700    1_
$a Khromova, Irina $u Centre for HIV/AIDS & Infectious Diseases, Kaliningrad, Russia
700    1_
$a Jilich, David $u Charles University in Prague and Na Bulovce Hospital, Prague, Czech Republic
700    1_
$a Rozplochowski, Blazej $u Poznan University of Medical Sciences, Poznan, Poland
700    1_
$a Oprea, Cristiana $u Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
700    1_
$a Peters, Lars $u Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK
710    2_
$a EuroSIDA study
773    0_
$w MED00188131 $t Open forum infectious diseases $x 2328-8957 $g Roč. 7, č. 12 (2020), s. ofaa470
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33409325 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210413 $b ABA008
991    __
$a 20210610101352 $b ABA008
999    __
$a ind $b bmc $g 1649741 $s 1130616
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 7 $c 12 $d ofaa470 $e 20201007 $i 2328-8957 $m Open forum infectious diseases $n Open Forum Infect Dis $x MED00188131
LZP    __
$a Pubmed-20210413

Find record

Citation metrics

Archiving options